THE RESEARCH: Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Researchers compiled treatment data and audiograms from 451 childhood cancer survivors (CCS) treated at seven pediatric oncology centers in the Netherlands. The study focused on identifying patients that had received platinum agents without cranial irradiation since no previous studies have looked at ototoxicity outcomes in this population. Risk factors evaluated for the development of hearing impairment included the impact of co-medications, type of platinum agent (cisplatin or carboplatin), and cumulative dose received.
